Medicilon Won Four Heavyweight Awards in One Fell Swoop!

“Top 50 Listed Companies for Growth”

“Top Ten Entrepreneurship Leaders of Listed Companies”

“Excellent Secretary of the Board of Directors of Listed Companies on the Science and Technology Innovation Board”

“Information Disclosure Outstanding Board Secretary Award”

On September 28, the list of “15th China Listed Company Value Selection”, sponsored by Securities Times and specially co-organized by Caitong Securities, was officially announced.  Shanghai Medicilon Inc. (Medicilon) stood out from thousands of participating companies with its outstanding comprehensive strength and won four heavyweight awards.

“China Listed Company Value Selection” adopts quantitative and qualitative methods, through comparisonand calculation of various financial, investment and other indicators of listed companies, combined with the research and judgment of industry organization on corporate governance and finance.  More than 20 experts from regulatory agencies, academia, securities firms, and funds reviewed the list of candidates and finally selected each award.  The selection has become one of the most influential selections in the field of listed companies sponsored by Chinese mainstream financial media.

Innovation drives growth and quality leads development. Medicilon has successfully been listed in the “Top 50 Listed Companies for Growth” with its outstanding performance in technological innovation, continuous increase in R&D investment, and growth.

In the first half of 2021 alone, Medicilon achieved operating income of RMB 485 million, a year-on-year increase of 86.26%; net profit was RMB 113 million, a year-on-year increase of 142.29%, and R&D expenses were RMB 34 million, an increase of RMB 14.48 million from the same period last year, an increase of 77.04%.  During the reporting period, the company developed, improved and innovated a series of new drug R&D technologies, and possessed mature modeling technologies for more than 430 drug efficacy models. (Data source: Medicilon’s 2021 semi-annual report)

The high growth is inseparable from the scientific research team with strong execution ability, and also inseparable from the management team with excellent leadership.  As a pioneer in the field of pharmaceutical, Medicilon Founder & CEO, Dr. Chunlin Chen, won the title of “Top Ten Entrepreneurial Leaders of Listed Companies” with his legendary entrepreneurial life, keen insight and forward-looking vision.

“He was the first college student in his hometown after the Chinese Economic Refore. The idea of changing the medical conditions in his hometown allowed him to devote himself to the biopharmaceutical industry.  He is an elegant scholar, with the mission of “serving the country with medicine”, he has built the world’s leading comprehensive drug R&D outsourcing service platform.  “Winning glory for the Chinese pharmaceutical industry and glory for the Chinese nation” has become his supreme ideal forever. “

–Top Ten Entrepreneurship Leaders Award Presentation

In addition, Mr. Guolin Wang, the director and secretary of the board of Medicilon, was awarded the “Excellent Secretary of the Board of Listed Companies on the Science and Technology Innovation Board” and “Information Disclosure Outstanding Board Secretary Award” for his hard work in the position of Secretary of the Board and his outstanding achievements in promoting the steady development of the company.  This is not only a commendation and affirmation of Mr. Wang’s years of work, but also a full affirmation of the company’s management team in terms of corporate governance, information disclosure, and investor relations management.

Every honor is inseparable from a support. This support comes from every client, partner, and scientific researcher.  So far, Medicilon has provided new drug research and development services to more than 1,100 clients worldwide. While achieving the dream of new drugs, Medicilon has achieved today’s Medicilon.

Medicilon continues to increase its investment in technology, pays attention to the transformation of R&D and scientific and technological innovation results, improves operation and management capabilities, and maintains enterprising vitality and innovation power.  Medicilon will contribute to the healthy and sustainable development of the STAR and the capital market, and create more value for shareholders and society.